The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.

Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.

Principia Biopharma, whose drug discovery platform is based on research at UCSF, has completed a $122m initial public offering after underwriters exercised their greenshoe option.

Karolinska Development has celebrated an exit as Umeå spinout Asarina Pharma went public in Sweden after raising $16.3m in its initial public offering.

The immuno-oncology therapy developer's investors include UC’s office of the chief investment officer, which contributed to a $300m round in January.

A month after Sutro closed an $85.4m series E round, the cancer drug developer, based on research at Stanford, has filed for a $75m initial public offering.

Ascentage Pharma, based on research at University of Michigan, has filed to list in Hong Kong having raised about $235m in funding.

Principia Biopharma, whose drug discovery platform is based on research at UCSF, has filed for an $86.3m initial public offering having raised $50m earlier this month.

Sensyne Health has completed a $76m initial public offering and will begin trading on Aim tomorrow, offering an exit to University of Oxford.

The Johns Hopkins-backed antibody developer floated above its range and has seen its stock almost double in price.